CA2171869A1 - Proteines/polypeptides nouveaux et plasmides de cotransfection; vehicules recombinants vivants utiles pour ces produits - Google Patents

Proteines/polypeptides nouveaux et plasmides de cotransfection; vehicules recombinants vivants utiles pour ces produits

Info

Publication number
CA2171869A1
CA2171869A1 CA002171869A CA2171869A CA2171869A1 CA 2171869 A1 CA2171869 A1 CA 2171869A1 CA 002171869 A CA002171869 A CA 002171869A CA 2171869 A CA2171869 A CA 2171869A CA 2171869 A1 CA2171869 A1 CA 2171869A1
Authority
CA
Canada
Prior art keywords
protein
coronavirus
modified
coding
fipv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002171869A
Other languages
English (en)
Inventor
Michel Bublot
Catherine De Wannemaeker
Didier Colau
Philippe Roux-Salembien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimminaco AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2171869A1 publication Critical patent/CA2171869A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

On décrit des protéines à activité antigénique destinées à être utilisées dans des compositions de vaccins contre les coronavirus. Les protéines à activité antigénique sont des protéines de coronavirus dénommées protéine S et protéines SM. La protéine S présente des régions antigéniques A1, A2 et/ou D modifiées, supprimées ou bien absentes, de manière à empêcher le phénomène de l'intensification dépendante des anticorps. Le peptide de signal de la protéine S peut être également modifié ou supprimé. L'invention concerne des procédés de préparation des séquences de codage de l'ADN codant pour ces protéines à activité antigénique ainsi que des procédés de formulation des protéines ou des séquences de codage de l'ADN codant ces dernières dans des vecteurs pharmaceutiquement acceptables, y compris des vecteurs recombinants vivants destinés à protéger les mammifères contre les infections à coronavirus. Les protéines et les vaccins à activité antigénique ci-décrits sont notamment dirigés contre la péritonite infectieuse féline et permet de protéger les felins contre les infections à virus de la péritonite inféctieuse féline.
CA002171869A 1993-09-16 1994-09-07 Proteines/polypeptides nouveaux et plasmides de cotransfection; vehicules recombinants vivants utiles pour ces produits Abandoned CA2171869A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9319212.8 1993-09-16
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same

Publications (1)

Publication Number Publication Date
CA2171869A1 true CA2171869A1 (fr) 1995-03-23

Family

ID=10742112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002171869A Abandoned CA2171869A1 (fr) 1993-09-16 1994-09-07 Proteines/polypeptides nouveaux et plasmides de cotransfection; vehicules recombinants vivants utiles pour ces produits

Country Status (10)

Country Link
EP (1) EP0720654A1 (fr)
JP (1) JPH09509562A (fr)
KR (1) KR960705047A (fr)
AU (1) AU7615894A (fr)
BR (1) BR9407507A (fr)
CA (1) CA2171869A1 (fr)
GB (2) GB2282601B (fr)
NO (1) NO961086L (fr)
WO (1) WO1995007987A2 (fr)
ZA (1) ZA946887B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
FR2741806B1 (fr) * 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
AU3650197A (en) * 1996-07-05 1998-02-02 Vanderbilt University Mutated antibody-dependent infection enhancing domains of hiv
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
CN1223605C (zh) * 2003-05-16 2005-10-19 中国科学院微生物研究所 抑制sars冠状病毒的多肽药物及其衍生物和其应用
CN113321714B (zh) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 SARS-CoV-2的重组N蛋白及其制备与纯化方法
WO2022055978A1 (fr) * 2020-09-08 2022-03-17 The Trustees Of The University Of Pennsylvania Compositions et méthodes de diminution de risque de maladie amplifiée par vaccin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
JPS63123385A (ja) * 1986-09-05 1988-05-27 デュファル・インテルナチオナル・レセールフ・ベー・ヴェー 新規抗原的活性蛋白質およびぺプチド、並びにネコ科感染性腹膜炎ウイルスワクチン
CA2005291C (fr) * 1988-12-30 1999-01-26 Beverly Dale Instruments de diagnostic du virus de la peritonite infectieuse des felins
HUT54733A (en) * 1989-07-12 1991-03-28 Duphar Int Res Process for producing new, antigenically active proteins and peptides, as well as feline infectious peritonitis virus (fipv) vaccines
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
CA2128698A1 (fr) * 1992-02-18 1993-08-19 Richard G. Olsen Vaccin contre la peritonite feline infectieuse et methode de preparation
ES2182827T3 (es) * 1992-05-08 2003-03-16 Pfizer Gen del virus corona canino y usos del mismo.
JPH07508176A (ja) * 1992-05-08 1995-09-14 ファイザー・インコーポレイテッド 普遍コロナウイルスワクチン

Also Published As

Publication number Publication date
GB2282601A (en) 1995-04-12
BR9407507A (pt) 1997-01-07
EP0720654A1 (fr) 1996-07-10
WO1995007987A2 (fr) 1995-03-23
GB2316681A (en) 1998-03-04
ZA946887B (en) 1995-06-27
WO1995007987A3 (fr) 1995-06-22
AU7615894A (en) 1995-04-03
NO961086L (no) 1996-05-09
GB2282601B (en) 1998-04-15
GB2316681B (en) 1998-04-15
GB9319212D0 (en) 1993-11-03
NO961086D0 (no) 1996-03-15
JPH09509562A (ja) 1997-09-30
KR960705047A (ko) 1996-10-09
GB9722558D0 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
CA2239072C (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
CA2031164C (fr) Herpesvirus recombinant de dindons et vaccins de vecteur vivant qui en sont derives
EP0835133B1 (fr) Compositions recombinantes et compositions combinees de virus de la rage et de la variole, et leurs utilisations
NZ333546A (en) Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus
EP0640097A1 (fr) Compositions et procedes de vaccination contre les coronavirus
CA2171869A1 (fr) Proteines/polypeptides nouveaux et plasmides de cotransfection; vehicules recombinants vivants utiles pour ces produits
CA2099069C (fr) Vaccin recombinant anti-herpesvirus du chat
WO2002000881A1 (fr) Pseudo-particules virales du virus de la diarrhee virale des bovins (bvd)
EP0606452B1 (fr) Vaccins vecteurs d'herpesvirus felin recombine
NZ253188A (en) Vaccines and mutants in relation to infectious bovine rhinotracheitis virus
US5674499A (en) Equine herpesvirus gene 15 mutants
EP0668355B1 (fr) Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
JPH06253852A (ja) Ｃｃｖワクチン
CA2136381A1 (fr) Vecteur d'herpesvirus bovin de type 1 servant de vaccin

Legal Events

Date Code Title Description
FZDE Dead